Addressing Problematic Opioid Use in OECD Countries

References

[78] Abdul-Quader, A. et al. (2013), “Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review”, AIDS and Behavior, Vol. 17/9, pp. 2878-2892, http://dx.doi.org/10.1007/s10461-013-0593-y.

[118] ABIM Foundation (2018), Choosing Wisely - Our Mission, http://www.choosingwisely.org/our-mission/ (accessed on 31 October 2018).

[120] ABIM Foundation (2018), Updates on an Epidemic: Efforts to Promote Safe Opioid Prescribing | Choosing Wisely, http://www.choosingwisely.org/resources/updates-from-the-field/updates-on-an-epidemic-efforts-to-promote-safe-opioid-prescribing/ (accessed on 31 October 2018).

[11] Adewumi, A. et al. (2018), “Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose”, CNS Drugs, Vol. 32/2, pp. 101-116, http://dx.doi.org/10.1007/s40263-018-0499-3.

[24] AEMPS (2019), Utilización de medicamentos opioides en España durante el periodo 2010-2017, Agencia Española de Medicamentos y Productos Sanitarios, https://www.aemps.gob.es/medicamentosUsoHumano/observatorio/informes-publicados/informes-opioides-espana-2010-2017.htm (accessed on 26 March 2019).

[245] AIHW (2018), Alcohol and other drug treatment services in Australia, Australian Institute of Health and Welfare, Canberra, http://www.aihw.gov.au (accessed on 25 March 2019).

[26] AIHW (2018), Opioid harm in Australia and comparisons between Australia and Canada, Australian Institute of Health and Welfare, Canberra, http://www.aihw.gov.au (accessed on 16 January 2019).

[244] AIHW (2016), Australian Burden of Disease Study: Impact and causes of illness and death in Australia 2011, Australian Institute of Health and Welfare, Canberra, https://www.aihw.gov.au/getmedia/d4df9251-c4b6-452f-a877-8370b6124219/19663.pdf.aspx?inline=true (accessed on 16 January 2019).

[111] Alford, D. et al. (2015), “SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.”, Pain Medicine, Vol. 17/1, pp. n/a-n/a, http://dx.doi.org/10.1111/pme.12878.

[256] AMA (2018), Opioid prescribing letters to GPs, Australian Medical Association, https://ama.com.au/gp-network-news/opioid-prescribing-letters-gps (accessed on 16 January 2019).

[152] Amato, L. et al. (2011), “Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification”, Cochrane Database of Systematic Reviews 9, http://dx.doi.org/10.1002/14651858.CD005031.pub4.

[153] Amato, L. et al. (2011), “Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence”, Cochrane Database of Systematic Reviews 10, http://dx.doi.org/10.1002/14651858.CD004147.pub4.

[75] Annan, K. et al. (2017), The opioid crisis in North America, Global Commission on Drug Policy.

[168] ANSM (2018), Spray nasal de naloxone (Nalscue) : entrée en vigueur de l’AMM le 8 janvier 2018 - ANSM : Agence nationale de sécurité du médicament et des produits de santé, https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Spray-nasal-de-naloxone-Nalscue-entree-en-vigueur-de-l-AMM-le-8-janvier-2018 (accessed on 25 March 2019).

[84] Arkes, J. (2007), “Does the economy affect teenage substance use?”, Health Economics, Vol. 16/1, pp. 19-36, http://dx.doi.org/10.1002/hec.1132.

[161] Australian Department of Health (2018), National Drug Strategy 2017–2026, https://campaigns.health.gov.au/drughelp/resources/publications/report/national-drug-strategy-2017-2026 (accessed on 21 October 2018).

[243] Australian Institute of Health and Welfare (2018), Alcohol, tobacco and other drugs in Australia - Illicit opioids (heroin), https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia/contents/drug-types/illicit-opioids-heroin (accessed on 5 September 2018).

[60] Bair, M. and A. Bohnert (2015), “Overdoses in Patients on Opioids: Risks Associated with Mental Health Conditions and Their Treatment”, Journal of General Internal Medicine, Vol. 30/8, pp. 1051-1053, http://dx.doi.org/10.1007/s11606-015-3332-4.

[135] Ballantyne, J., E. Kalso and C. Stannard (2016), “WHO analgesic ladder: a good concept gone astray.”, BMJ (Clinical research ed.), Vol. 352, p. i20, http://dx.doi.org/10.1136/BMJ.I20.

[128] Bao, Y. et al. (2018), “Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions”, Health Affairs, Vol. 37/10, pp. 1596-1604, http://dx.doi.org/10.1377/hlthaff.2018.0512.

[156] Beaton, A., C. Shubkin and S. Chapman (2016), “Addressing substance misuse in adolescents: a review of the literature on the screening, brief intervention, and referral to treatment model.”, Current opinion in pediatrics, Vol. 28/2, pp. 258-65, http://dx.doi.org/10.1097/MOP.0000000000000333.

[173] Belani, H. and P. Muennig (2008), “Cost-Effectiveness of Needle and Syringe Exchange for the Prevention of HIV in New York City”, Journal of HIV/AIDS & Social Services, Vol. 7/3, pp. 229-240, http://dx.doi.org/10.1080/15381500802307492.

[240] Binswanger, I. and A. Gordon (2016), “From risk reduction to implementation: Addressing the opioid epidemic and continued challenges to our field”, Substance Abuse, Vol. 37/1, pp. 1-3, http://dx.doi.org/10.1080/08897077.2015.1134152.

[107] Bohnert, A., G. Guy and J. Losby (2018), “Opioid Prescribing in the United States Before and After the Centers for Disease Control and Prevention’s 2016 Opioid Guideline”, Annals of Internal Medicine, Vol. 169/6, p. 367, http://dx.doi.org/10.7326/M18-1243.

[230] Bonnie, R., M. Ford and J. Phillips (eds.) (2017), Pain Management and the Opioid Epidemic, National Academies Press, Washington, D.C., http://dx.doi.org/10.17226/24781.

[191] Bowen Matthew, D. (2018), Un-burying the Lead: Public health tools are the key to beating the opioid epidemic, USC-Brookings Schaeffer Initiative for Health Policy, https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1- (accessed on 16 December 2018).

[162] Bray, J. et al. (2017), “Screening, Brief Intervention and Referral to Treatment (SBIRT): rationale, program overview and cross-site evaluation”, Addiction, Vol. 112, pp. 3-11, http://dx.doi.org/10.1111/add.13676.

[140] British Columbia Ministry of Health (2017), A Guideline for the Clinical Management of Opioid Use Disorders, British Columbia Ministry of Health, http://www.bccsu.ca/care-guidance-publications/ (accessed on 5 November 2018).

[7] Brummett, C. et al. (2017), “New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults”, JAMA Surgery, Vol. 152/6, p. e170504, http://dx.doi.org/10.1001/jamasurg.2017.0504.

[141] Bruneau, J. et al. (2018), “Management of opioid use disorders: a national clinical practice guideline.”, CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne, Vol. 190/9, pp. E247-E257, http://dx.doi.org/10.1503/cmaj.170958.

[199] Brunette, M., K. Mueser and R. Drake (2004), “A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders”, Drug and Alcohol Review, Vol. 23/4, pp. 471-481, http://dx.doi.org/10.1080/09595230412331324590.

[177] Brunt, T. (2017), Drug checking as a harm reduction tool for recreational drug users: opportunities and challenges | www.emcdda.europa.eu, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), http://www.emcdda.europa.eu/document-library/drug-checking-pill-testing-harm-reduction-tool-recreational-drug-users-opportunities-and-challenges_en (accessed on 14 December 2018).

[132] Bundesamt für Justiz (2018), BtMVV - Verordnung über das Verschreiben, die Abgabe und den Nachweis des Verbleibs von Betäubungsmitteln, https://www.gesetze-im-internet.de/btmvv_1998/BJNR008000998.html (accessed on 14 December 2018).

[88] Burkey, M., Y. A. Kim and W. Breakey (2011), “The Role of Social Ties in Recovery in a Population of Homeless Substance Abusers”, Addictive Disorders & Their Treatment, Vol. 10/1, pp. 14-20, http://dx.doi.org/10.1097/ADT.0b013e3181ea7511.

[108] Busse, J. et al. (2017), “Guideline for opioid therapy and chronic noncancer pain.”, CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne, Vol. 189/18, pp. E659-E666, http://dx.doi.org/10.1503/cmaj.170363.

[85] Carpenter, C., C. McClellan and D. Rees (2017), “Economic conditions, illicit drug use, and substance use disorders in the United States”, Journal of Health Economics, Vol. 52, pp. 63-73, http://dx.doi.org/10.1016/j.jhealeco.2016.12.009.

[201] Catto, M. and N. Thomson (2008), “Review of illicit drug use among Indigenous peoples”, ECU Publications Pre. 2011, http://ro.ecu.edu.au/ecuworks/889 (accessed on 13 September 2018).

[253] CDC Injury Center (2018), Understanding the Epidemic | Opioid Overdose, https://www.cdc.gov/drugoverdose/epidemic/index.html (accessed on 27 August 2018).

[35] CDC-NCHS (2018), National Center for Health Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention. United States of America, https://www.cdc.gov/nchs/index.htm (accessed on 26 October 2018).

[189] Chambers, D. et al. (2018), “Systematic review of the evidence on housing interventions for ‘housing-vulnerable’ adults and its relationship to wellbeing”, http://eprints.whiterose.ac.uk/131241/ (accessed on 22 October 2018).

[58] Charumilind, S. et al. (2018), Why we need bolder action to combat the opioid epidemic, McKinsey & Company, https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/why-we-need-bolder-action-to-combat-the-opioid-epidemic?cid=other-eml-alt-mip-mck-oth-1809&hlkid=4438e5df8b9f464a960c2d04ef9fa963&hctky=9745658&hdpid=7e241590-d1e5-4439-8abb- (accessed on 24 October 2018).

[19] Chenaf, C. et al. (2019), “Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality”, European Journal of Pain, Vol. 23/1, pp. 124-134, http://dx.doi.org/10.1002/ejp.1291.

[79] Chimbar, L. and Y. Moleta (2018), “Naloxone Effectiveness”, Journal of Addictions Nursing, Vol. 29/3, pp. 167-171, http://dx.doi.org/10.1097/JAN.0000000000000230.

[55] Chiu, A. et al. (2018), “Trainees as Agents of Change in the Opioid Epidemic: Optimizing the Opioid Prescription Practices of Surgical Residents”, Journal of Surgical Education, Vol. 75/1, pp. 65-71, http://dx.doi.org/10.1016/j.jsurg.2017.06.020.

[121] Choosing Wisely Canada (2018), Opioid Wisely - Choosing Wisely Canada, Choosing Wisely Canada, https://choosingwiselycanada.org/campaign/opioid-wisely/ (accessed on 31 October 2018).

[5] Chou, R. et al. (2015), “The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop”, Annals of Internal Medicine, Vol. 162/4, p. 276, http://dx.doi.org/10.7326/M14-2559.

[41] Christie, C. et al. (2017), US Presidential Commission on Opioids, https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-1-2017.pdf (accessed on 17 August 2018).

[248] CIHI (2018), Pan-Canadian Trends in the Prescribing of Opioids and Benzodiazepines, 2012 to 2017, CIHI, Ottawa, ON, https://www.cihi.ca/sites/default/files/document/opioid-prescribing-june2018-en-web.pdf (accessed on 28 August 2018).

[30] CIHI (2018), Types of Opioid Harms in Canadian Hospitals: Comparing Canada and Australia, Canadian Institute for Health Information, Ottawa, ON.

[202] CMS (2017), CMS announces new Medicaid policy to combat the opioid crisis by increasing access to treatment options | CMS, https://www.cms.gov/newsroom/press-releases/cms-announces-new-medicaid-policy-combat-opioid-crisis-increasing-access-treatment-options (accessed on 5 November 2018).

[232] Cochran, G. et al. (2018), “Prescription Opioid Quality Measures Applied Among Pennsylvania Medicaid Enrollees”, Journal of Managed Care & Specialty Pharmacy, Vol. 24/9, pp. 875-885, http://dx.doi.org/10.18553/jmcp.2018.24.9.875.

[169] Coffin, P. and S. Sullivan (2013), “Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal”, Annals of Internal Medicine, Vol. 158/1, p. 1, http://dx.doi.org/10.7326/0003-4819-158-1-201301010-00003.

[211] Collins, S., H. Lonczak and S. Clifasefi (2017), “Seattle’s Law Enforcement Assisted Diversion (LEAD): Program effects on recidivism outcomes”, Evaluation and Program Planning, Vol. 64, pp. 49-56, http://dx.doi.org/10.1016/J.EVALPROGPLAN.2017.05.008.

[212] Collins, S., H. Lonczak and S. Clifasefi (2015), LEAD Evaluation: Utilization and Cost Report 6/24/15 UW LEAD Evaluation Team 1 LEAD Program Evaluation: Criminal Justice and Legal System Utilization and Associated Costs, http://static1.1.sqspcdn.com/static/f/1185392/26401889/1437170937787/June+2015+LEAD-Program-Evaluation-Criminal-Justice-and-Legal-System-Utilization-and-Associated-Costs.pdf?token=18pk0dg8BICxwWSAT2fADsLAyLw%3D (accessed on 22 October 2018).

[196] Collins, S. et al. (2012), “Project-based Housing First for chronically homeless individuals with alcohol problems: within-subjects analyses of 2-year alcohol trajectories.”, American journal of public health, Vol. 102/3, pp. 511-9, http://dx.doi.org/10.2105/AJPH.2011.300403.

[207] Compton, W., M. Boyle and E. Wargo (2015), “Prescription opioid abuse: Problems and responses”, Preventive Medicine, Vol. 80, pp. 5-9, http://dx.doi.org/10.1016/J.YPMED.2015.04.003.

[91] Cooper, S. and S. Nielsen (2017), “Stigma and Social Support in Pharmaceutical Opioid Treatment Populations: a Scoping Review”, International Journal of Mental Health and Addiction, Vol. 15/2, pp. 452-469, http://dx.doi.org/10.1007/s11469-016-9719-6.

[190] CORNEIL, T. et al. (2006), “Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users”, Health & Place, Vol. 12/1, pp. 79-85, http://dx.doi.org/10.1016/j.healthplace.2004.10.004.

[34] Council of Economic Advisers (2017), The Underestimated Cost of the Opioid Crisis, Executive Office of the President of the United States, https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20Underestimated%20Cost%20of%20the%20Opioid%20Crisis.pdf (accessed on 27 August 2018).

[217] Csete, J. and D. Tomasini-Joshi (2016), Drug courts: Equivocal evidence on a popular intervention, Open Society Foundations, https://www.opensocietyfoundations.org/sites/default/files/drug-courts-equivocal-evidence-popular-intervention-20160928.pdf (accessed on 18 October 2018).

[188] Davis, K. and S. O’Neill (2005), “Special section on relapse prevention: A focus group analysis of relapse prevention strategies for persons with substance use and mental disorders.”, Psychiatric Services, Vol. 56/10, pp. 1288-1291, http://ps.psychiatryonline.org (accessed on 15 October 2018).

[13] Davis, M. et al. (2017), “Prescription Opioid Use among Adults with Mental Health Disorders in the United States.”, Journal of the American Board of Family Medicine : JABFM, Vol. 30/4, pp. 407-417, http://dx.doi.org/10.3122/jabfm.2017.04.170112.

[115] De Jong, C., L. Luycks and J. Delicat (2011), “The Master in Addiction Medicine Program in The Netherlands”, Substance Abuse, Vol. 32/2, pp. 108-114, http://dx.doi.org/10.1080/08897077.2011.555713.

[242] Degenhardt, L. et al. (2016), “The extent and correlates of community-based pharmaceutical opioid utilisation in Australia.”, Pharmacoepidemiology and drug safety, Vol. 25/5, pp. 521-38, http://dx.doi.org/10.1002/pds.3931.

[145] Degenhardt, L. et al. (2009), “Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved”, Drug and Alcohol Dependence, Vol. 105/1-2, pp. 9-15, http://dx.doi.org/10.1016/j.drugalcdep.2009.05.021.

[117] Department of Health (2019), Chief Medical Officer’s letters on opioid prescribing, http://www.health.gov.au/internet/main/publishing.nsf/content/opioid-prescribing (accessed on 6 May 2019).

[151] Dugosh, K. et al. (2016), “A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction.”, Journal of addiction medicine, Vol. 10/2, pp. 93-103, http://dx.doi.org/10.1097/ADM.0000000000000193.

[166] Dwyer, R. et al. (2018), “An overview of take-home naloxone programs in Australia”, Drug and Alcohol Review, Vol. 37/4, pp. 440-449, http://dx.doi.org/10.1111/dar.12812.

[23] Dzierżanowski, T. and A. Ciałkowska-Rysz (2017), “Accessibility of opioid analgesics and barriers to optimal chronic pain treatment in Poland in 2000–2015”, Supportive Care in Cancer, Vol. 25/3, pp. 775-781, http://dx.doi.org/10.1007/s00520-016-3460-3.

[2] ECDD-WHO, E. (2017), Carfentanil - Critical Review Report, World Health Organisation, Geneva, http://www.who.int/medicines/access/controlled-substances/Critical_Review_Carfentanil.pdf (accessed on 17 August 2018).

[229] EMCDDA (2018), 2018 European Drug Report, http://www.emcdda.europa.eu/edr2018_en (accessed on 17 October 2018).

[80] EMCDDA (2018), Drug consumption rooms: an overview of provision and evidence, http://www.emcdda.europa.eu/system/files/publications/2734/POD_Drug%20consumption%20rooms.pdf (accessed on 17 October 2018).

[223] EMCDDA (2018), Portugal Drug Report 2018, European Monitoring Centre for Drugs and Drug Addiction, http://www.emcdda.europa.eu/system/files/publications/8890/portugal-cdr-2018.pdf (accessed on 23 October 2018).

[93] EMCDDA (2017), Health and social responses to drug problems: a European guide, Publications Office of the European Union, http://www.emcdda.europa.eu/publications/manuals/health-and-social-responses-to-drug-problems-a-european-guide_en (accessed on 8 August 2018).

[227] EMCDDA (2016), Models for the legal supply of cannabis: recent developments, EMCDDA, Lisbon, http://www.emcdda.europa.eu/topics/pods/legal-supply-of-cannabis (accessed on 24 October 2018).

[184] EMCDDA (2012), New heroin-assisted treatment, http://www.emcdda.europa.eu/publications/insights/heroin-assisted-treatment_en (accessed on 22 October 2018).

[16] EMCDDA (2000), Annual Report on the State of the Drugs Problem in the European Union, https://www.ncjrs.gov/App/Publications/abstract.aspx?ID=186282 (accessed on 9 September 2018).

[64] EMCDDA and Europol (2017), Drugs and the darknet: perspectives for enforcement, research and policy, European Monitoring Centre for Drugs and Drug Addiction and Europol, http://dx.doi.org/10.2810/834620.

[137] Fabbri, A. et al. (2018), “Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.”, International journal of health policy and management, Vol. 7/6, pp. 504-509, http://dx.doi.org/10.15171/ijhpm.2018.20.

[139] Fédération Française d’Addictologie (2004), Stratégies thérapeutiques pour les personnes dépendantes des opiacés : place des traitements de substtitution, https://www.has-sante.fr/portail/upload/docs/application/pdf/TSO_court.pdf (accessed on 14 December 2018).

[226] Félix, S. and P. Portugal (2017), “Drug decriminalization and the price of illicit drugs”, International Journal of Drug Policy, Vol. 39, pp. 121-129, http://dx.doi.org/10.1016/J.DRUGPO.2016.10.014.

[182] Ferri, M., M. Davoli and C. Perucci (2011), “Heroin maintenance for chronic heroin-dependent individuals”, Cochrane Database of Systematic Reviews 12, http://dx.doi.org/10.1002/14651858.CD003410.pub4.

[63] Finklea, K. (2017), Dark Web, Congressional Research Service, The Library of US Congress, http://www.crs.gov (accessed on 9 September 2018).

[133] Finklea, K., L. Sacco and E. Bagalman (2014), Prescription Drug Monitoring Programs, Congressional research Service, http://www.crs.gov (accessed on 12 October 2018).

[186] Fitzpatrick, S., S. Johnsen and M. White (2011), “Multiple Exclusion Homelessness in the UK: Key Patterns and Intersections”, Social Policy and Society, Vol. 10/04, pp. 501-512, http://dx.doi.org/10.1017/S147474641100025X.

[236] Food and Drug Administration (2018), Drug Approvals and Databases - National Drug Code Directory, https://www.fda.gov/drugs/informationondrugs/ucm142438.htm (accessed on 13 December 2018).

[89] Fox, A. et al. (2016), “Untangling the Relationship Between Mental Health and Homelessness Among a Sample of Arrestees”, Crime & Delinquency, Vol. 62/5, pp. 592-613, http://dx.doi.org/10.1177/0011128713511571.

[12] Frisher, M. et al. (2012), Preventing opioid overdoses in Europe: A critical assessment of known risk factors and preventative measures, EMCDDA, http://www.drugs.ie/resourcesfiles/ResearchDocs/Europe/Research/2012/Preventing_overdose_report_EMCDDA.pdf (accessed on 22 August 2018).

[215] GAO (2011), Adult drug courts: Studies Show Courts Reduce Recidivism, but DOJ Could Enhance Future Performance Measure Revision Efforts, U.S. Government Accountability Office, Washington, DC, https://www.gao.gov/assets/590/586793.pdf (accessed on 18 October 2018).

[122] GAO (2002), State Monitoring Programs Provide Useful Tool to Reduce Diversion, United States General Accounting Office, https://www.gao.gov/new.items/d02634.pdf (accessed on 12 October 2018).

[83] Gitis, B. and I. Soto (2018), “The Labor Force and Output Consequences of the Opioid Crisis”, American Action Forum, https://www.americanactionforum.org/print/?url=https://www.americanactionforum.org/research/labor-force-output-consequences-opioid-crisis/ (accessed on 10 July 2018).

[92] Government of Canada (2018), Government of Canada Actions on Opioids: 2016 and 2017 - Canada.ca, https://www.canada.ca/en/health-canada/services/publications/healthy-living/actions-opioids-2016-2017.html (accessed on 17 October 2018).

[98] Government of Canada (2018), Opioids toolkit - Canada.ca, https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/resources-toolkit.html (accessed on 21 October 2018).

[142] Gowing, L., R. Ali and A. Dunlop (2014), National guidelines for medication-assisted treatment of opioid dependence, http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/Content/AD14DA97D8EE00E8CA257CD1001E0E5D/$File/endorsed%20MATOD%20guidelines%20accessible%20Apr2014%20(D14-1005149).DOCX (accessed on 6 November 2018).

[102] Gray, J. and N. Hagemeier (2012), “Prescription Drug Abuse and DEA-Sanctioned Drug Take-Back Events: Characteristics and Outcomes in Rural Appalachia”, Archives of Internal Medicine, Vol. 172/15, pp. 1186-1187, http://dx.doi.org/10.1001/archinternmed.2012.2374.

[165] Green, T., R. Heimer and L. Grau (2008), “Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States”, Addiction, Vol. 103/6, pp. 979-989, http://dx.doi.org/10.1111/j.1360-0443.2008.02182.x.

[225] Greenwald, G. (2009), “Drug Decriminalization in Portugal: Lessons for Creating Fair and Successful Drug Policies”, SSRN Electronic Journal, http://dx.doi.org/10.2139/ssrn.1464837.

[136] Guo, T., S. Sriram and P. Manchanda (2017), “The Effect of Information Disclosure on Industry Payments to Physicians”, SSRN Electronic Journal, http://dx.doi.org/10.2139/ssrn.3064769.

[114] Haber, P. and B. Murnion (2011), “Training in Addiction Medicine in Australia”, Substance Abuse, Vol. 32/2, pp. 115-119, http://dx.doi.org/10.1080/08897077.2011.555718.

[94] Hadden, K., L. Prince and C. Barnes (2016), “Health Literacy and Opioid Use in Orthopaedic Patients.”, Journal of surgical orthopaedic advances, Vol. 25/4, pp. 234-237, http://www.ncbi.nlm.nih.gov/pubmed/28244865 (accessed on 14 September 2018).

[47] Hadland, S. et al. (2018), “Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing”, JAMA Internal Medicine, Vol. 178/6, p. 861, http://dx.doi.org/10.1001/jamainternmed.2018.1999.

[106] Haegerich, T. et al. (2014), “What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose”, Drug and Alcohol Dependence, Vol. 145, pp. 34-47, http://dx.doi.org/10.1016/j.drugalcdep.2014.10.001.

[50] Haffajee, R. and M. Mello (2017), “Drug Companies’ Liability for the Opioid Epidemic”, New England Journal of Medicine, http://dx.doi.org/10.1056/NEJMp1710756.

[148] Hagan, H., E. Pouget and D. Des Jarlais (2011), “A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs”, Journal of Infectious Diseases, Vol. 204/1, pp. 74-83, http://dx.doi.org/10.1093/infdis/jir196.

[154] Hannes, K. et al. (2017), Adolescent’s experience and perceived effectiveness of self-help groups for addiction: a systematic review of qualitative research evidence prior to 2013, Centrum voor Sociologisch Onderzoek, Social Research Methodology Group; KU Leuven, https://limo.libis.be/primo-explore/fulldisplay?docid=LIRIAS1873610&context=L&vid=Lirias&search_scope=Lirias&tab=default_tab&lang=en_US&fromSitemap=1 (accessed on 14 September 2018).

[131] Hartung, D. et al. (2017), “Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes”, Substance Abuse, pp. 1-8, http://dx.doi.org/10.1080/08897077.2017.1389798.

[109] Häuser, W. et al. (2015), “Empfehlungen der aktualisierten Leitlinie LONTS”, Der Schmerz, Vol. 29/1, pp. 109-130, http://dx.doi.org/10.1007/s00482-014-1463-x.

[159] Hawk, K. and G. D’Onofrio (2018), “Emergency department screening and interventions for substance use disorders.”, Addiction science & clinical practice, Vol. 13/1, p. 18, http://dx.doi.org/10.1186/s13722-018-0117-1.

[138] Health Canada (2018), Minister of Health Ginette Petitpas Taylor announces intent to severely restrict marketing of opioids - Canada.ca, https://www.canada.ca/en/health-canada/news/2018/06/minister-of-health-ginette-petitpas-taylor-announces-intent-to-severely-restrict-marketing-of-opioids.html (accessed on 21 October 2018).

[97] Health Canada (2018), New regulations to provide better information for patients on the safe use of opioid medications - Canada.ca, https://www.canada.ca/en/health-canada/news/2018/05/new-regulations-to-provide-better-information-for-patients-on-the-safe-use-of-opioid-medications.html (accessed on 21 October 2018).

[206] Health Canada (2017), Royal Assent of Bill C-37 - An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts - Canada.ca, https://www.canada.ca/en/health-canada/news/2017/05/royal_assent_of_billc-37anacttoamendthecontrolleddrugsandsubstan.html (accessed on 17 October 2018).

[6] Higgins, C., B. Smith and K. Matthews (2018), “Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis”, British Journal of Anaesthesia, Vol. 120/6, pp. 1335-1344, http://dx.doi.org/10.1016/j.bja.2018.03.009.

[81] Hollingsworth, A., C. Ruhm and K. Simon (2017), “Macroeconomic conditions and opioid abuse”, Journal of Health Economics, Vol. 56, http://dx.doi.org/10.1016/j.jhealeco.2017.07.009.

[192] Housing First Europe Hub (2018), Home - Housing First Europe Hub, https://housingfirsteurope.eu/ (accessed on 29 April 2019).

[155] HSE Primary Care Division (2014), Clinical Guidelines for Opioid Substitution Treatment, Health Service Executive, http://www. (accessed on 15 December 2018).

[14] Hser, Y. et al. (2015), “Long-Term Course of Opioid Addiction”, Harvard Review of Psychiatry, Vol. 23/2, pp. 76-89, http://dx.doi.org/10.1097/HRP.0000000000000052.

[228] Hughes, C. et al. (2016), Decriminalisation of drug use and possession in Australia – A briefing note | NDARC - National Drug and Alcohol Research Centre, https://ndarc.med.unsw.edu.au/resource/decriminalisation-drug-use-and-possession-australia-briefing-note (accessed on 17 October 2018).

[224] Hughes, C. and A. Stevens (2010), “What Can We Learn From The Portuguese Decriminalization of Illicit Drugs?”, British Journal of Criminology, Vol. 50/6, pp. 999-1022, http://dx.doi.org/10.1093/bjc/azq038.

[28] INCB (2018), International Narcotics Control Board, https://www.incb.org/ (accessed on 26 October 2018).

[205] INCB (2018), Report of the International Narcotics Control Board for 2017, http://www.incb.org (accessed on 17 October 2018).

[222] Jakubowski, A. et al. (2018), “Knowledge of the 911 Good Samaritan Law and 911-calling behavior of overdose witnesses”, Substance Abuse, Vol. 39/2, pp. 233-238, http://dx.doi.org/10.1080/08897077.2017.1387213.

[147] Jarvis, B. et al. (2018), “Extended-release injectable naltrexone for opioid use disorder: a systematic review”, Addiction, Vol. 113/7, pp. 1188-1209, http://dx.doi.org/10.1111/add.14180.

[252] Johnson, K. et al. (2018), “Federal Response to the Opioid Crisis”, Current HIV/AIDS Reports, Vol. 15/4, pp. 293-301, http://dx.doi.org/10.1007/s11904-018-0398-8.

[254] Jones, C., E. Einstein and W. Compton (2018), “Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016”, JAMA, Vol. 319/17, p. 1819, http://dx.doi.org/10.1001/jama.2018.2844.

[68] Jones, C., L. Paulozzi and K. Mack (2014), “Alcohol Involvement in Opioid Pain Reliever and Benzodiazepine Drug Abuse–Related Emergency Department Visits and Drug-Related Deaths — United States, 2010”, MMWR Morb Mortal Wkly Rep, Vol. 63/40, pp. 881-885, https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6340a1.htm (accessed on 22 January 2019).

[181] Karamouzian, M. et al. (2018), “Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada.”, Harm reduction journal, Vol. 15/1, p. 46, http://dx.doi.org/10.1186/s12954-018-0252-8.

[185] Keane, M. (2007), Social reintegration as a response to drug use in Ireland., Dublin: Health Research Board, http://www.hrb.ie/ndc (accessed on 21 October 2018).

[130] Keast, S. et al. (2018), “Effects of a prior authorization policy for extended-release/long-acting opioids on utilization and outcomes in a state Medicaid program”, Addiction, Vol. 113/9, pp. 1651-1660, http://dx.doi.org/10.1111/add.14248.

[101] Kennedy-Hendricks, A. et al. (2016), “Medication Sharing, Storage, and Disposal Practices for Opioid Medications Among US Adults”, JAMA Internal Medicine, Vol. 176/7, p. 1027, http://dx.doi.org/10.1001/jamainternmed.2016.2543.

[178] Kerr, T. and K. Tupper (2017), Drug checking as a harm reduction intervention: Evidence Review Report, BC Centre on Substance Use (BCCSU), https://www.bccsu.ca/wp-content/uploads/2017/12/Drug-Checking-Evidence-Review-Report.pdf (accessed on 13 December 2018).

[195] Kirst, M. et al. (2015), “The impact of a Housing First randomized controlled trial on substance use problems among homeless individuals with mental illness”, http://dx.doi.org/10.1016/j.drugalcdep.2014.10.019.

[18] Knaul, F. et al. (2018), “Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report”, The Lancet, Vol. 391/10128, pp. 1391-1454, http://dx.doi.org/10.1016/S0140-6736(17)32513-8.

[42] Kolodny, A. et al. (2015), “The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction”, Annual Review of Public Health, Vol. 36/1, http://dx.doi.org/10.1146/annurev-publhealth-031914-122957.

[73] Kolodny, A. and T. Frieden (2017), Ten steps the federal government should take now to reverse the opioid addiction epidemic, http://dx.doi.org/10.1001/jama.2017.14567.

[4] Kosten, T. and T. George (2002), “The neurobiology of opioid dependence: implications for treatment.”, Science & practice perspectives, Vol. 1/1, pp. 13-20, http://www.ncbi.nlm.nih.gov/pubmed/18567959 (accessed on 2 July 2018).

[57] Kroenke, K. and A. Cheville (2017), “Management of Chronic Pain in the Aftermath of the Opioid Backlash”, JAMA, Vol. 317/23, p. 2365, http://dx.doi.org/10.1001/jama.2017.4884.

[82] Krueger, A. (2017), Where Have All the Workers Gone? An Inquiry into the Decline of the U.S. Labor Force Participation Rate, https://www.brookings.edu/wp-content/uploads/2017/09/1_krueger.pdf (accessed on 21 August 2018).

[65] Kruithof, K. et al. (2016), Internet-facilitated drugs trade: An analysis of the size, scope and the role of the Netherlands, RAND Corporation, http://dx.doi.org/10.7249/RR1607.

[170] Langham, S. et al. (2018), “Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom”, Value in Health, Vol. 21/4, pp. 407-415, http://dx.doi.org/10.1016/j.jval.2017.07.014.

[72] Larjow, E. et al. (2016), “A Systematic Content Analysis of Policy Barriers Impeding Access to Opioid Medication in Central and Eastern Europe: Results of ATOME”, Journal of Pain and Symptom Management, Vol. 51/1, pp. 99-107, http://dx.doi.org/10.1016/J.JPAINSYMMAN.2015.08.012.

[149] Larney, S. et al. (2017), “Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.”, The Lancet. Global health, Vol. 5/12, pp. e1208-e1220, http://dx.doi.org/10.1016/S2214-109X(17)30373-X.

[194] Latimer, E. et al. (2014), At Home/Chez Soi Project: Montréal Site Final Report, Mental Health Commission of Canada, Calgary, http://www.mentalhealthcommission.ca (accessed on 29 April 2019).

[234] Lawrinson, P., J. Copeland and D. Indig (2005), “Development and validation of a brief instrument for routine outcome monitoring in opioid maintenance pharmacotherapy services: The brief treatment outcome measure (BTOM)”, Drug and Alcohol Dependence, Vol. 80/1, pp. 125-133, http://dx.doi.org/10.1016/J.DRUGALCDEP.2005.04.001.

[17] Lawson, C. (2018), “America’s 150-Year Opioid Epidemic”, The New York Times, https://www.nytimes.com/2018/05/19/opinion/sunday/opioid-epidemic-history.html.

[210] LEAD (2018), Law Enforcement Assisted Diversion (LEAD), http://leadkingcounty.org/ (accessed on 22 October 2018).

[39] Leung, P. et al. (2017), “A 1980 Letter on the Risk of Opioid Addiction”, New England Journal of Medicine, Vol. 376/22, http://dx.doi.org/10.1056/NEJMc1700150.

[119] Levinson, W. et al. (2015), “’Choosing Wisely’: a growing international campaign.”, BMJ quality & safety, Vol. 24/2, pp. 167-74, http://dx.doi.org/10.1136/bmjqs-2014-003821.

[53] Lin, D. et al. (2018), “Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers”, JAMA Network Open, Vol. 1/2, p. e180235, http://dx.doi.org/10.1001/jamanetworkopen.2018.0235.

[48] Lin, D. et al. (2017), “Financial Conflicts of Interest and the Centers for Disease Control and Prevention’s 2016 Guideline for Prescribing Opioids for Chronic Pain”, JAMA Internal Medicine, Vol. 177/3, p. 427, http://dx.doi.org/10.1001/jamainternmed.2016.8471.

[90] Livingston, J. et al. (2012), “The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review”, Addiction, Vol. 107/1, pp. 39-50, http://dx.doi.org/10.1111/j.1360-0443.2011.03601.x.

[214] Mackey, T. et al. (2018), “Solution to Detect, Classify, and Report Illicit Online Marketing and Sales of Controlled Substances via Twitter: Using Machine Learning and Web Forensics to Combat Digital Opioid Access.”, Journal of medical Internet research, Vol. 20/4, p. e10029, http://dx.doi.org/10.2196/10029.

[70] Ma, J. et al. (2018), “Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis”, Molecular Psychiatry, p. 1, http://dx.doi.org/10.1038/s41380-018-0094-5.

[51] Makary, M., H. Overton and P. Wang (2017), “Overprescribing is major contributor to opioid crisis.”, BMJ (Clinical research ed.), Vol. 359, p. j4792, http://dx.doi.org/10.1136/bmj.j4792.

[74] Maksabedian Hernandez, E. (2017), Increasing Access to Medication-Assisted Treatment for Opioid Use Disorders: Estimating Costs, Supply, and the Effects of Insurance Expansions, http://dx.doi.org/10.7249/RGSD404.

[66] Martin, J. et al. (2018), “The international darknet drugs trade—a regional analysis of cryptomarkets”, in Rick Brown (ed.), Organised crime research in Australia 2018, Australian Institute of Criminology, Canberra, https://researchoutput.csu.edu.au/ws/portalfiles/portal/22519166/22290075_Research_report.pdf#page=101 (accessed on 22 October 2018).

[144] Mattick, R. et al. (2014), “Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence”, Cochrane Database of Systematic Reviews 2, p. CD002207, http://dx.doi.org/10.1002/14651858.CD002207.pub4.

[143] Mattick, R. et al. (2009), “Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence”, Cochrane Database of Systematic Reviews 3, p. CD002209, http://dx.doi.org/10.1002/14651858.CD002209.pub2.

[100] Maughan, B. et al. (2016), “Unused opioid analgesics and drug disposal following outpatient dental surgery: A randomized controlled trial”, Drug and Alcohol Dependence, Vol. 168, pp. 328-334, http://dx.doi.org/10.1016/j.drugalcdep.2016.08.016.

[175] May, T., T. Bennett and K. Holloway (2018), “The impact of medically supervised injection centres on drug-related harms: A meta-analysis”, International Journal of Drug Policy, Vol. 59, pp. 98-107, http://dx.doi.org/10.1016/j.drugpo.2018.06.018.

[96] McCarthy, D. et al. (2015), “Improving Patient Knowledge and Safe Use of Opioids: A Randomized Controlled Trial”, Academic Emergency Medicine, Vol. 22/3, pp. 331-339, http://dx.doi.org/10.1111/acem.12600.

[46] McCaskill, C. (2018), HSGAC, Minority Staff Report. Combating the opioid epidemic: Intercepting Illicit Opioids at Ports of Entry UNITED STATES SENATE Committee on Homeland Security & Governmental Affairs Ranking Member, United States Senate. Committee on Homeland Security & Governmental Affairs, https://www.cdc.gov/drugoverdose/data/fentanyl.html (accessed on 14 September 2018).

[221] McClellan, C. et al. (2018), “Opioid-overdose laws association with opioid use and overdose mortality”, Addictive Behaviors, Vol. 86, pp. 90-95, http://dx.doi.org/10.1016/J.ADDBEH.2018.03.014.

[36] McQueen, K. and J. Murphy-Oikonen (2016), “Neonatal Abstinence Syndrome”, New England Journal of Medicine, Vol. 375/25, pp. 2468-2479, http://dx.doi.org/10.1056/NEJMra1600879.

[37] Metz, V. et al. (2018), “Characteristics of drug use among pregnant women in the United States: Opioid and non-opioid illegal drug use”, Drug and Alcohol Dependence, Vol. 183, pp. 261-266, http://dx.doi.org/10.1016/J.DRUGALCDEP.2017.11.010.

[216] Mitchell, O. et al. (2012), “Drug courts’ effects on criminal offending for juveniles and adults - The Campbell Collaboration”, The Campbell Collaboration, Vol. 4, http://dx.doi.org/10.4073/csr.2012.4.

[9] Muhuri, P., J. Gfroerer and M. Davies (2013), Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States, SAMHSA - CBHSQ Data Review, https://www.samhsa.gov/data/report/associations-nonmedical-pain-reliever-use-and-initiation-heroin-use-united-states (accessed on 17 August 2018).

[27] Muller, A. et al. (2019), “Prescribed opioid analgesic use developments in three Nordic countries, 2006–2017”, Scandinavian Journal of Pain, Vol. 0/0, http://dx.doi.org/10.1515/sjpain-2018-0307.

[255] Murphy, S. et al. (2017), Mortality in the United States, 2017 Key findings Data from the National Vital Statistics System, https://www.cdc.gov/nchs/data/databriefs/db328_tables-508.pdf#1. (accessed on 25 March 2019).

[21] Musazzi, U. et al. (2018), “Do laws impact opioids consumption? A breakpoint analysis based on Italian sales data”, Journal of Pain Research, Vol. Volume 11, pp. 1665-1672, http://dx.doi.org/10.2147/JPR.S163438.

[86] Nagelhout, G. et al. (2017), “How economic recessions and unemployment affect illegal drug use: A systematic realist literature review.”, The International journal on drug policy, Vol. 44, pp. 69-83, http://dx.doi.org/10.1016/j.drugpo.2017.03.013.

[235] Neale, J. et al. (2016), “DEVELOPMENT AND VALIDATION OF ‘SURE’: A PATIENT REPORTED OUTCOME MEASURE (PROM) FOR RECOVERY FROM DRUG AND ALCOHOL DEPENDENCE”, Drug and Alcohol Dependence, Vol. 165, pp. 159-167, http://dx.doi.org/10.1016/J.DRUGALCDEP.2016.06.006.

[174] Nguyen, T. et al. (2014), “Syringe exchange in the United States: a national level economic evaluation of hypothetical increases in investment.”, AIDS and behavior, Vol. 18/11, pp. 2144-55, http://dx.doi.org/10.1007/s10461-014-0789-9.

[146] Nielsen, S. et al. (2016), “Opioid agonist treatment for pharmaceutical opioid dependent people”, Cochrane Database of Systematic Reviews 5, http://dx.doi.org/10.1002/14651858.CD011117.pub2.

[239] NIH (2019), HEAL Initiative Research Plan, National Institutes of Health. U.S. Department of Health and Human Services, https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/heal-initiative-research-plan (accessed on 26 April 2019).

[105] Nuckols, T. et al. (2014), “Opioid Prescribing: A Systematic Review and Critical Appraisal of Guidelines for Chronic Pain”, Annals of Internal Medicine, Vol. 160/1, pp. 38-47, http://dx.doi.org/10.7326/0003-4819-160-1-201401070-00732.

[247] O’Connor, S., V. Grywacheski and K. Louie (2018), “At-a-glance - Hospitalizations and emergency department visits due to opioid poisoning in Canada”, Health Promotion and Chronic Disease Prevention in Canada, Vol. 38/6, pp. 244-247, http://dx.doi.org/10.24095/hpcdp.38.6.04.

[62] OECD (2018), Governance Frameworks to Counter Illicit Trade, Illicit Trade, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264291652-en.

[203] OECD (2018), Governance Frameworks to Counter Illicit Trade, Illicit Trade, OECD Publishing, Paris, http://dx.doi.org/10.1787/9789264291652-en.

[33] OECD (2018), OECD Economic Surveys: United States 2018, OECD Publishing, Paris, http://dx.doi.org/10.1787/eco_surveys-usa-2018-en.

[187] OECD (2015), Integrating Social Services for Vulnerable Groups: Bridging Sectors for Better Service Delivery, OECD Publishing, Paris, https://dx.doi.org/10.1787/9789264233775-en.

[231] OFMA (2019), Observatoire Français des Médicaments Antalgiques, http://www.ofma.fr/ (accessed on 25 March 2019).

[95] Olsen, Y. and J. Sharfstein (2014), “Confronting the Stigma of Opioid Use Disorder—and Its Treatment”, JAMA, Vol. 311/14, p. 1393, http://dx.doi.org/10.1001/jama.2014.2147.

[246] Orpana, H. et al. (2018), “Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study”, Health Promotion and Chronic Disease Prevention in Canada, Vol. 38/6, pp. 234-243, http://dx.doi.org/10.24095/hpcdp.38.6.03.

[127] Pardo, B. (2017), “Do more robust prescription drug monitoring programs reduce prescription opioid overdose?”, Addiction, Vol. 112/10, pp. 1773-1783, http://dx.doi.org/10.1111/add.13741.

[126] Patrick, S. et al. (2016), “Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates”, Health Affairs, Vol. 35/7, pp. 1324-1332, http://dx.doi.org/10.1377/hlthaff.2015.1496.

[258] PBS (2014), Opioid Analgesics: Overview, Drug utilisation sub-committee, Pharmaceutical Benefits Scheme (PBS), Australia, http://www.pbs.gov.au/info/industry/listing/participants/public-release-docs/opioids/opioid-analgesics-overview (accessed on 16 January 2019).

[77] Pierce, M. et al. (2016), “Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England.”, Addiction (Abingdon, England), Vol. 111/2, pp. 298-308, http://dx.doi.org/10.1111/add.13193.

[10] Pitt, A., K. Humphreys and M. Brandeau (2018), “Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic.”, American journal of public health, Vol. 108/10, pp. 1394-1400, http://dx.doi.org/10.2105/AJPH.2018.304590.

[171] Platt, L. et al. (2017), “Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs”, Cochrane Database of Systematic Reviews 9, http://dx.doi.org/10.1002/14651858.CD012021.pub2.

[40] Portenoy, R. and K. Foley (1986), “Chronic use of opioid analgesics in non-malignant pain: report of 38 cases.”, Pain, Vol. 25/2, pp. 171-86, http://www.ncbi.nlm.nih.gov/pubmed/2873550 (accessed on 17 August 2018).

[38] Porter, J. and H. Jick (1980), “Addiction rare in patients treated with narcotics.”, The New England journal of medicine, Vol. 302/2, p. 123, http://www.ncbi.nlm.nih.gov/pubmed/7350425 (accessed on 17 August 2018).

[176] Potier, C. et al. (2014), “Supervised injection services: What has been demonstrated? A systematic literature review”, Drug and Alcohol Dependence, Vol. 145, pp. 48-68, http://dx.doi.org/10.1016/j.drugalcdep.2014.10.012.

[237] PubChem (2018), The PubChem Project, https://pubchem.ncbi.nlm.nih.gov/ (accessed on 13 December 2018).

[213] Quintana, P. et al. (2017), “The hidden web and the fentanyl problem: Detection of ocfentanil as an adulterant in heroin”, International Journal of Drug Policy, Vol. 40, pp. 78-83, http://dx.doi.org/10.1016/j.drugpo.2016.10.006.

[220] Rees, D. et al. (2017), With a Little Help from My Friends: The Effects of Naloxone Access and Good Samaritan Laws on Opioid-Related Deaths, National Bureau of Economic Research, Cambridge, MA, http://dx.doi.org/10.3386/w23171.

[52] Reidenberg, M. and O. Willis (2007), “Prosecution of Physicians for Prescribing Opioids to Patients”, Clinical Pharmacology & Therapeutics, Vol. 81/6, pp. 903-906, http://dx.doi.org/10.1038/sj.clpt.6100127.

[124] Reifler, L. et al. (2012), “Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse?”, Pain Medicine, Vol. 13/3, pp. 434-442, http://dx.doi.org/10.1111/j.1526-4637.2012.01327.x.

[200] Reif, S. et al. (2014), “Recovery Housing: Assessing the Evidence”, Psychiatric Services, Vol. 65/3, pp. 295-300, http://dx.doi.org/10.1176/appi.ps.201300243.

[219] Rezansoff, S. et al. (2015), “Beyond recidivism: changes in health and social service involvement following exposure to drug treatment court.”, Substance abuse treatment, prevention, and policy, Vol. 10, p. 42, http://dx.doi.org/10.1186/s13011-015-0038-x.

[150] Rich, K. et al. (2018), “Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?”, Current HIV/AIDS Reports, Vol. 15/3, pp. 266-275, http://dx.doi.org/10.1007/s11904-018-0396-x.

[241] Roxburgh, A. et al. (2018), Opioid-, amphetamine-, and cocaine-induced deaths in Australia: August 2018, National Drug and Alcohol Research Centre, UNSW, https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Drug%20Induced%20deaths%20August%202018%20Drug%20Trends%20Bulletin.pdf (accessed on 5 September 2018).

[125] Rutkow, L. et al. (2015), “Effect of Florida’s Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use”, JAMA Internal Medicine, Vol. 175/10, p. 1642, http://dx.doi.org/10.1001/jamainternmed.2015.3931.

[250] Scholl, L. et al. (2018), “Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017”, MMWR. Morbidity and Mortality Weekly Report, Vol. 67/5152, http://dx.doi.org/10.15585/mmwr.mm6751521e1.

[158] Schonfeld, L. et al. (2015), “Screening, Brief Intervention, and Referral to Treatment for Older Adults With Substance Misuse.”, American journal of public health, Vol. 105/1, pp. 205-211, http://dx.doi.org/10.2105/AJPH.2013.301859.

[20] Schubert, I., P. Ihle and R. Sabatowski (2013), “Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data.”, Deutsches Arzteblatt international, Vol. 110/4, pp. 45-51, http://dx.doi.org/10.3238/arztebl.2013.0045.

[257] ScriptWise (2018), National Mandatory Real-Time Prescription Monitoring, https://www.scriptwise.org.au/real-time-monitoring/ (accessed on 16 January 2019).

[218] Sevigny, E., B. Fuleihan and F. Ferdik (2013), “Do drug courts reduce the use of incarceration?: A meta-analysis”, Journal of Criminal Justice, Vol. 41/6, pp. 416-425, http://dx.doi.org/10.1016/J.JCRIMJUS.2013.06.005.

[179] Sherman, S. and T. Green (2018), Fentanyl Overdose Reduction Checking Analysis Study, Johns Hopkins-Bloomberg School of Public Health, https://www.cdc.gov/media/releases/2017/s1027-fentanyl- (accessed on 13 December 2018).

[59] Skelly, A. et al. (2018), Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review, http://dx.doi.org/10.23970/AHRQEPCCER209.

[71] Sordo, L. et al. (2017), “Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies”, the bmj BMJ BMJ, Vol. 357357, http://dx.doi.org/10.1136/bmj.j1550.

[31] Special Advisory Committee on the Epidemic of Opioid Overdoses (2019), National report: Apparent opioid-related deaths in Canada (January 2016 to September 2018), Web-based Report, https://infobase.phac-aspc.gc.ca/datalab/national-surveillance-opioid-harms-mortality.html (accessed on 26 April 2019).

[110] Stanek, J., M. Renslow and L. Kalliainen (2015), “The Effect of an Educational Program on Opioid Prescription Patterns in Hand Surgery: A Quality Improvement Program”, The Journal of Hand Surgery, Vol. 40/2, pp. 341-346, http://dx.doi.org/10.1016/J.JHSA.2014.10.054.

[249] Statistics Canada (2018), Survey on Opioid Awareness, 2017, https://www150.statcan.gc.ca/n1/pub/11-627-m/11-627-m2018001-eng.htm (accessed on 28 August 2018).

[157] Sterling, S. et al. (2015), “Implementation of Screening, Brief Intervention, and Referral to Treatment for Adolescents in Pediatric Primary Care”, JAMA Pediatrics, Vol. 169/11, p. e153145, http://dx.doi.org/10.1001/jamapediatrics.2015.3145.

[104] Stewart, H. et al. (2015), “Inside Maine’s Medicine Cabinet: Findings From the Drug Enforcement Administration’s Medication Take-Back Events”, American Journal of Public Health, Vol. 105/1, pp. e65-e71, http://dx.doi.org/10.2105/AJPH.2014.302207.

[172] Stone, K. and S. Shirley-Beavan (2018), Global State of Harm Reduction 2018, Harm Reduction International, London, http://www.hri.global (accessed on 29 January 2019).

[167] Strang, J. (2016), Preventing opioid overdose deaths with take-home naloxone -, Publications Office of the EU, https://publications.europa.eu/en/publication-detail/-/publication/96fcb410-b831-11e5-8d3c-01aa75ed71a1/language-en (accessed on 17 December 2018).

[183] Strang, J. et al. (2015), “Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction”, British Journal of Psychiatry, Vol. 207/01, pp. 5-14, http://dx.doi.org/10.1192/bjp.bp.114.149195.

[69] Strang, J. et al. (2016), Preventing opioid overdose deaths with take-home naloxone, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), http://dx.doi.org/10.2810/357062.

[76] Substance Abuse and Mental Health Services Administration (2017), National Survey of Substance Abuse Treatment Services (N-SSATS): 2016 Data on Substance Abuse Treatment Facilities, https://www.samhsa.gov/data/sites/default/files/2016_NSSATS.pdf (accessed on 22 August 2018).

[251] Substance Abuse and Mental Health Services Administration (n.d.), Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health, (HHS Publication No. SMA 17-5044, NSDUH Series H-52), https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.htm.

[197] Sumnall, H. and A. Brotherhood (2012), “Social reintegration and employment: evidence and interventions for drug users in treatment”, http://dx.doi.org/10.2810/72023.

[204] Suzuki, J. and S. El-Haddad (2017), “A review: Fentanyl and non-pharmaceutical fentanyls”, Drug and Alcohol Dependence, Vol. 171, pp. 107-116, http://dx.doi.org/10.1016/J.DRUGALCDEP.2016.11.033.

[15] Tavitian-Exley, I. et al. (2015), “Influence of different drugs on HIV risk in people who inject: systematic review and meta-analysis”, Addiction, Vol. 110/4, pp. 572-584, http://dx.doi.org/10.1111/add.12846.

[134] TGA (2019), Codeine information hub, Therapeutic Goods Administration - Department of Health, Australian Government, https://www.tga.gov.au/codeine-info-hub (accessed on 29 April 2019).

[99] The Royal College of Anaesthetists and Public Health England (2018), Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain The Royal College of Anaesthetists, https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware (accessed on 14 December 2018).

[129] TMMDA (2019), Renkli Reçete Bilgi Sistemi - Turkish Medicines and Medical Devices Agency, https://renklirecete.saglik.gov.tr/ (accessed on 18 April 2019).

[193] Tsemberis, S. (2010), Housing first : the Pathways model to end homelessness for people with mental illness and addiction.

[180] Tupper, K. et al. (2018), “Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting”, Drug and Alcohol Dependence, Vol. 190, pp. 242-245, http://dx.doi.org/10.1016/J.DRUGALCDEP.2018.06.020.

[1] United Nations Office on Drugs and Crime, U. (2016), Terminology and Information on Drugs, https://www.unodc.org/documents/scientific/Terminology_and_Information_on_Drugs-3rd_edition.pdf (accessed on 24 July 2018).

[116] University Health Network (2018), Chronic Pain & Opioid Stewardship – Project ECHO® at University Health Network, https://uhn.echoontario.ca/chronic-pain-opioid-stewardship/ (accessed on 5 November 2018).

[29] UNODC (2018), Drugs data | Statistics and Data, https://dataunodc.un.org/drugs (accessed on 26 October 2018).

[3] UNODC (2017), Global SMART Update: Fentanyl and its analogues-50 years on, http://www.unodc.org/ (accessed on 16 October 2018).

[61] US Drug Enforcement Administration (2017), National Drug Threat Assessment, https://www.overdosefreepa.pitt.edu/wp-content/uploads/2017/10/2017-NDTA-1.pdf (accessed on 22 August 2018).

[43] US Senate, H. (2017), Fueling an Epidemic Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups, https://www.hsgac.senate.gov/imo/media/doc/REPORT-Fueling%20an%20Epidemic-Exposing%20the%20Financial%20Ties%20Between%20Opioid%20Manufacturers%20and%20Third%20Party%20Advocacy%20Groups.pdf (accessed on 20 August 2018).

[49] US Western District Court of Virginia (2007), Case decision Case No. 1:07CR00029, http://www.vawd.uscourts.gov/OPINIONS/JONES/107CR00029.PDF (accessed on 20 August 2018).

[44] Van Zee, A. (2009), The promotion and marketing of oxycontin: Commercial triumph, public health tragedy, http://dx.doi.org/10.2105/AJPH.2007.131714.

[238] Volkow, N. and F. Collins (2017), “The Role of Science in Addressing the Opioid Crisis”, New England Journal of Medicine, Vol. 377/4, pp. 391-394, http://dx.doi.org/10.1056/NEJMsr1706626.

[22] Wagemaakers, F. et al. (2017), “Opioid analgesic use in Australia and The Netherlands: a cross-country comparison”, International Journal of Clinical Pharmacy, Vol. 39/4, pp. 874-880, http://dx.doi.org/10.1007/s11096-017-0492-9.

[208] Wagner, K. et al. (2016), “Training law enforcement to respond to opioid overdose with naloxone: Impact on knowledge, attitudes, and interactions with community members”, Drug and Alcohol Dependence, Vol. 165, pp. 22-28, http://dx.doi.org/10.1016/J.DRUGALCDEP.2016.05.008.

[164] Walley, A. et al. (2013), “Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.”, BMJ (Clinical research ed.), Vol. 346, p. f174, http://dx.doi.org/10.1136/BMJ.F174.

[198] Walton, M. and M. Hall (2016), “The Effects of Employment Interventions on Addiction Treatment Outcomes: A Review of the Literature”, Journal of Social Work Practice in the Addictions, Vol. 16/4, pp. 358-384, http://dx.doi.org/10.1080/1533256X.2016.1235429.

[209] Watson, T. et al. (2018), “Creating and sustaining cooperative relationships between supervised injection services and police: A qualitative interview study of international stakeholders”, International Journal of Drug Policy, Vol. 61, pp. 1-6, http://dx.doi.org/10.1016/j.drugpo.2018.08.001.

[56] Webster, F. et al. (2017), “From Opiophobia to Overprescribing: A Critical Scoping Review of Medical Education Training for Chronic Pain.”, Pain medicine (Malden, Mass.), Vol. 18/8, pp. 1467-1475, http://dx.doi.org/10.1093/pm/pnw352.

[54] Webster, L. et al. (2011), “An Analysis of the Root Causes for Opioid-Related Overdose Deaths in the United States”, Pain Medicine, Vol. 12/suppl 2, pp. S26-S35, http://dx.doi.org/10.1111/j.1526-4637.2011.01134.x.

[113] Welle-Strand, G. (2015), “Development of a Full Medical Specialty in Addiction Medicine Addiction Medicine : The Norwegian Experience”, in Textbook of Addiction Treatment: International Perspectives, Springer Milan, Milano, http://dx.doi.org/10.1007/978-88-470-5322-9_69.

[163] WHO and UNDOC (2014), Opioid overdose: preventing and reducing opioid overdose mortality, http://www.who.int/hiv/pub/idu/opioid_overdose/en/ (accessed on 16 October 2018).

[45] Whyte, L., G. Mulvihill and B. Wieder (2016), Politics of pain: Drugmakers fought state opioid limits amid crisis | Center for Public Integrity, https://www.publicintegrity.org/2016/09/18/20200/politics-pain-drugmakers-fought-state-opioid-limits-amid-crisis (accessed on 20 August 2018).

[233] Williams, A., E. Nunes and M. Olfson (2017), To Battle The Opioid Overdose Epidemic, Deploy The ‘Cascade of Care’ Model, Health Affairs Blog, http://dx.doi.org/10.1377/hblog20170313.059163.

[67] Winstock, A. et al. (2018), Global Drug Survey (GDS) 2018, https://www.globaldrugsurvey.com/gds-2018/ (accessed on 3 September 2018).

[8] World Drug Report (2018), World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9), https://www.unodc.org/wdr2018 (accessed on 6 July 2018).

[123] Worley, J. (2012), “Prescription Drug Monitoring Programs, a Response to Doctor Shopping: Purpose, Effectiveness, and Directions for Future Research”, Issues in Mental Health Nursing, Vol. 33/5, pp. 319-328, http://dx.doi.org/10.3109/01612840.2011.654046.

[103] Yanovitzky, I. (2016), “The American Medicine Chest Challenge: Evaluation of a Drug Take-Back and Disposal Campaign.”, Journal of studies on alcohol and drugs, Vol. 77/4, pp. 549-55, http://www.ncbi.nlm.nih.gov/pubmed/27340957 (accessed on 16 October 2018).

[32] Ye, X. et al. (2018), “At-a-glance - Impact of drug overdose-related deaths on life expectancy at birth in British Columbia”, Health Promotion and Chronic Disease Prevention in Canada, Vol. 38/6, pp. 248-251, http://dx.doi.org/10.24095/hpcdp.38.6.05.

[160] Young, M. et al. (2014), “Effectiveness of brief interventions as part of the Screening, Brief Intervention and Referral to Treatment (SBIRT) model for reducing the nonmedical use of psychoactive substances: a systematic review”, Systematic Reviews, Vol. 3/1, p. 50, http://dx.doi.org/10.1186/2046-4053-3-50.

[87] Zerger, S. (2012), “Housing: A fundamental component of drug policy”, International Journal of Drug Policy, Vol. 23/2, pp. 91-93, http://dx.doi.org/10.1016/j.drugpo.2011.12.001.

[25] Zin, C., L. Chen and R. Knaggs (2014), “Changes in trends and pattern of strong opioid prescribing in primary care.”, European journal of pain (London, England), Vol. 18/9, pp. 1343-51, http://dx.doi.org/10.1002/j.1532-2149.2014.496.x.

[112] Zolekar, A. et al. (2018), “Outcomes Related to Opioid Prescribing after Academic Detailing: A Review of Literature”, Value in Health, Vol. 21, p. S265, http://dx.doi.org/10.1016/j.jval.2018.04.1770.